221 related articles for article (PubMed ID: 15160935)
21. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia.
Steinbach D; Sell W; Voigt A; Hermann J; Zintl F; Sauerbrey A
Leukemia; 2002 Aug; 16(8):1443-7. PubMed ID: 12145683
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Su Y; Lee SH; Sinko PJ
Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
[TBL] [Abstract][Full Text] [Related]
23. Effect of the breast-cancer resistance protein on atypical multidrug resistance.
Lage H; Dietel M
Lancet Oncol; 2000 Nov; 1():169-75. PubMed ID: 11905655
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia.
Sargent JM; Williamson CJ; Maliepaard M; Elgie AW; Scheper RJ; Taylor CG
Br J Haematol; 2001 Nov; 115(2):257-62. PubMed ID: 11703319
[TBL] [Abstract][Full Text] [Related]
25. Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).
Paturi DK; Kwatra D; Ananthula HK; Pal D; Mitra AK
Int J Pharm; 2010 Jan; 384(1-2):32-8. PubMed ID: 19782742
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
27. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
28. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
Wang X; Nitanda T; Shi M; Okamoto M; Furukawa T; Sugimoto Y; Akiyama S; Baba M
Biochem Pharmacol; 2004 Oct; 68(7):1363-70. PubMed ID: 15345326
[TBL] [Abstract][Full Text] [Related]
29. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Natarajan K; Xie Y; Baer MR; Ross DD
Biochem Pharmacol; 2012 Apr; 83(8):1084-103. PubMed ID: 22248732
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
32. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.
Xia CQ; Yang JJ; Gan LS
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):595-611. PubMed ID: 16863427
[TBL] [Abstract][Full Text] [Related]
34. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.
Haimeur A; Conseil G; Deeley RG; Cole SP
Curr Drug Metab; 2004 Feb; 5(1):21-53. PubMed ID: 14965249
[TBL] [Abstract][Full Text] [Related]
35. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
37. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.
Ifergan I; Shafran A; Jansen G; Hooijberg JH; Scheffer GL; Assaraf YG
J Biol Chem; 2004 Jun; 279(24):25527-34. PubMed ID: 15047700
[TBL] [Abstract][Full Text] [Related]
38. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
Ahmed-Belkacem A; Pozza A; Macalou S; Pérez-Victoria JM; Boumendjel A; Di Pietro A
Anticancer Drugs; 2006 Mar; 17(3):239-43. PubMed ID: 16520651
[TBL] [Abstract][Full Text] [Related]
40. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]